Lumos Pharma (NASDAQ:LUMO) Given “Neutral” Rating at HC Wainwright

Lumos Pharma (NASDAQ:LUMO)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $4.25 price objective on the stock, down from their prior price objective of $28.00. HC Wainwright’s target price suggests a potential downside of 2.52% from the stock’s current price.

Other analysts also recently issued reports about the stock. Oppenheimer cut their target price on shares of Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. EF Hutton Acquisition Co. I raised shares of Lumos Pharma to a “strong-buy” rating in a research note on Tuesday, September 24th.

Lumos Pharma Stock Performance

NASDAQ:LUMO remained flat at $4.36 during trading hours on Thursday. 411,850 shares of the company’s stock traded hands, compared to its average volume of 48,181. The business’s fifty day simple moving average is $3.74 and its 200 day simple moving average is $2.81. Lumos Pharma has a 52 week low of $1.37 and a 52 week high of $4.58. The firm has a market capitalization of $35.39 million, a price-to-earnings ratio of -0.95 and a beta of 0.78.

Lumos Pharma (NASDAQ:LUMO) last announced its earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.33. Lumos Pharma had a negative net margin of 2,405.72% and a negative return on equity of 157.99%. The company had revenue of $0.49 million for the quarter. During the same period last year, the firm earned ($1.09) earnings per share. Equities analysts anticipate that Lumos Pharma will post -2.96 EPS for the current fiscal year.

Institutional Trading of Lumos Pharma

A hedge fund recently raised its stake in Lumos Pharma stock. Private Advisor Group LLC increased its position in shares of Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 744,513 shares of the company’s stock after acquiring an additional 714,500 shares during the period. Private Advisor Group LLC owned about 9.17% of Lumos Pharma worth $2,881,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 33.99% of the company’s stock.

About Lumos Pharma

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.